Financing channel feed

Alzheon IPO take two: Will in­vestors back a down­sized of­fer­ing from an Alzheimer’s biotech?

7 years ago

Vivek Ra­maswamy bags $100M in risk cap­i­tal to back his lat­est PhI­II gam­ble at Der­ma­vant — while Urovant dives in­to gene ther­a­py

7 years ago
People

Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

7 years ago
China

Y-mAbs’ sto­ry comes in­to the light: a ship­ping ty­coon, the MSK re­searcher, a par­tial hold and a $92M IPO gam­ble

7 years ago

New­ly part­nered with blue­bird, Grit­stone seeks $80M IPO in fi­nal dash for clin­ic

7 years ago

Japan­ese bil­lion­aire Hi­roshi Mik­i­tani bankrolls As­pyr­i­an with a $150M mega-round, back­ing a glob­al roll­out plan for PhI­II can­cer ther­a­py

7 years ago

New­born bio­bet­ter, biosim­i­lar mak­er Mabpharm pitch­es the lat­est biotech IPO in Hong Kong

7 years ago
China

Con­struc­tion sources buzzing about a new set of headaches and hur­dles fac­ing As­traZeneca’s be­lea­guered, $650M HQ project

7 years ago

Right on the heels of $150M raise, As­cen­t­age files the lat­est in a rush of HKEX biotech IPOs — but is the mar­ket too jit­tery?

7 years ago
China

Hous­ing As­traZeneca's old R&D ef­forts in an­tibi­otics, En­ta­sis files for $86M IPO

7 years ago

Ab­b­Vie, Sanofi-backed Prin­cip­ia of­fers an $86M IPO af­ter burn­ing through $148M for pipeline work

7 years ago

Der­ma­tol­ogy biotech Blue­ber­ry Ther­a­peu­tics banks $12M Se­ries B — and new part­ners in Asia

7 years ago

Bil­lion­aire-backed Ju­ve­nes­cence spins out an­ti-ag­ing, AI start­up Na­pa Ther­a­peu­tics

7 years ago
Startups
AI

Fresh from haul­ing in GSK’s bud­get-priced gene ther­a­py group, Or­chard har­vests $150M mega-round. Is it time to IPO?

7 years ago
Cell/Gene Tx

Back to the be­gin­ning: Pfiz­er seeds dis­cov­ery-stage neu­ro start­up Mag­no­lia (af­ter ax­ing its own brain R&D)

7 years ago
Startups

Pfiz­er, No­var­tis jump in­to an $84M de­vel­op­ment round for UK can­cer drug stars at Ar­tios

7 years ago

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

7 years ago
China

Tap­ping Chi­nese in­vestors, Apex­i­gen clos­es $73M for 8 tri­als in I/O

7 years ago
Startups

BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

7 years ago
China

Third Rock­'s Am­bys hauls $140M for liv­er dis­ease, ink­ing Take­da deal ahead of launch

7 years ago
Startups

Sam­sung out­lines block­buster in­vest­ment plan for bio­phar­ma­ceu­ti­cals, part of a $22B play on next-gen tech

7 years ago
AI

Min­ing re­al world da­ta for drug de­vel­op­ment in­sights, Wood­ford-backed AI firm seeks $77M Lon­don IPO

7 years ago

NEA, 5AM back a $50M play to steer gene ther­a­pies to the clin­ic at Ak­ou­os — the lat­est start­up in hear­ing

7 years ago
Startups

What's big­ger than a uni­corn? Sa­mumed stuns yet again as an­ti-ag­ing pipeline draws $438M at $12B val­u­a­tion

7 years ago
First page Previous page 124125126127128129130 Next page Last page
A service from the Financial Times